• Ardelyx's kidney disease drug hits goal in phase 3, teeing it up for FDA filing

    2 days ago - By Fierce Biotech

    A phase 3 trial of Ardelyx's tenapanor in chronic kidney disease patients on dialysis has met its primary endpoint. The success comes months after tenapanor hit the mark in another pivotal clinical trial, putting Ardelyx on track to file for approval in the indication around the middle of next year.
    Read more ...